0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > OX40

OX40

OX40 Molecule Information

Name:Tumor necrosis factor receptor superfamily member 4
Target Synonym:CD134;TNF Receptor Superfamily Member 4;OX40;Lymphoid Activation Antigene ACT35;OX40L receptor;TAX transcriptionally-activated glycoprotein 1 receptor;ACT35 antigen;TXGP1L;OX40 Cell Surface Antigen;IMD16;TNFRSF4
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:14
Lastest Research Phase:Phase ?

OX40 Part of Bioactivity data

OX0-H5252-Cell-based assay
FACS assay shows that recombinant Biotinylated FACS

FACS assay shows that recombinant Human OX40, Mouse IgG2a Fc Tag, low endotoxin (Cat. No. OX0-H5252) can bind to 293T cell overexpressing human OX40L. The concentration of OX40 is 0.01 μg/mL (Routinely tested).

TN4-H82E4-Cell-based assay
FACS assay shows that recombinant Biotinylated FACS

FACS assay shows that Biotinylated Human OX40, Avitag,His Tag (recommended for biopanning) (Cat. No. TN4-H82E4) can bind to 293T cell overexpressing human OX40L. The concentration of OX40 is 0.1 μg/mL (Routinely tested).

OX0-H5252-ELISA
Human OX40, Mouse IgG2a Fc Tag, low endotoxin Human OX40, Mouse IgG2a Fc Tag, low endotoxin  (Cat. No. OX0-H5252) ELISA bioactivity

Immobilized Human OX40 Ligand, His Tag (Cat. No. OXL-H52Q8) at 2 μg/mL (100 μL/well) can bind Human OX40, Mouse IgG2a Fc Tag, low endotoxin (Cat. No. OX0-H5252) with a linear range of 0.78-25 ng/mL (QC tested).

OX0-M82E5-ELISA
Biotinylated Mouse OX40, His,AvitagBiotinylated Mouse OX40, His,Avitag (Cat. No. OX0-M82E5) ELISA bioactivity

Immobilized Mouse OX40 Ligand, His Tag (Cat. No. TN4-M5241) at 2 μg/mL (100 μL/well) can bind Biotinylated Mouse OX40, His,Avitag (Cat. No. OX0-M82E5) with a linear range of 0.6-10 ng/mL (QC tested).

OX40 Protein Product ListCompare or Buy

OX40 Molecule Synonym Name

TNFRSF4,OX40,CD134,OX40L receptor,ACT35,TXGP1L

OX40 Molecule Background

Tumor necrosis factor receptor superfamily member 4 (TNFRSF4) is also known as ACT35 antigen, OX40L receptor, TAX transcriptionally-activated glycoprotein 1 receptor, CD antigen CD134, OX40. OX40 / TNFRSF4 contains four TNFR-Cys repeats. TNFRSF4 is receptor for TNFSF4 / OX40L / GP34 and can interacts with TRAF2, TRAF3 and TRAF5.

OX40 References

OX40 Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
INCAGN-1949 INCAGN-1949 Phase Ⅱ Agenus, Ludwig Institute for Cancer Research, Incyte Urogenital cancer, Renal cell carcinoma, Solid tumours Details
BGB-A445 BGB-A445 Phase Ⅰ BeiGene Solid tumours Details
Efizonerimod alfa MEDI-6383,MEDI6383 Phase Ⅰ MedImmune Solid tumours Details
GSK3174998 GSK-3174998; GSK 3174998; GSK3174998 Phase Ⅱ GlaxoSmithKline Solid tumours, Head and neck cancer Details
FS-120 FS-120 IND Filing F-star Cancer Details
PF-04518600 PF-04518600; PF-8600 Phase Ⅱ Pfizer Renal cell carcinoma, Breast cancer, Solid tumours Details
SL-279252 SL-279252; TAK-252 Phase Ⅰ Shattuck Labs Gastric adenocarcinoma, Non small cell lung cancer (NSCLC), Diffuse large B cell lymphoma, Renal cell carcinoma, Urothelial cancer, Solid tumours, Squamous cell carcinoma of head and neck cancer (SCCHN), Hodgkin lymphoma, Gastroesophageal junction adenocarcinoma, Melanoma Details
INBRX-106 INBRX-106 Phase Ⅰ Inhibrx Solid tumours Details
BMS-986178 BMS-986178 Phase Ⅱ Bristol-Myers Squibb Solid tumours Details
Recombinant human anti-OX40 monoclonal antibody (Livzon Group) Phase Ⅰ Livzon Pharmaceutical Group Cancer Details
MEDI-6469 MEDI-6469 Phase Ⅱ AgonOx, Providence Cancer Center, MedImmune Diffuse large B cell lymphoma, Prostate cancer, Breast cancer, Colorectal cancer, Head and neck cancer, Melanoma Details
Recombinant human anti-OX40 monoclonal antibody (Innovent Biologics) IBI-101,IBI101 Phase Ⅰ Innovent Biologics Cancer Details
KHK-4083 KHK-4083 Phase Ⅱ Kyowa Hakko Kirin Ulcerative colitis Details
ATOR-1015 ATOR-1015; ADC-1015 Phase Ⅰ Alligator Bioscience Solid tumours Details
Tavolimab MEDI-0562,MEDI0562 Phase Ⅱ MedImmune Ovarian cancer Details
GBR-830 GBR-830  Phase Ⅱ Glenmark Pharmaceuticals Atopic dermatitis Details
Vonlerolizumab RO-7021608; MOXR-0916; RG-7888 Phase Ⅱ Genentech Solid tumours Details

This web search service is supported by Google Inc.

totop